Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
Xenetic Biosciences' systemic DNase technology has entered clinical evaluation for the first time, with the first patient dosed in a study combining DNase I with anti-CD19 CAR T-cell therapy in large B-cell lymphoma at Israel's Ichilov Center. The investigator-initiated study, sponsored by the medical center and approved by the Israeli Ministry of Health, will enroll 12 patients with stable or progressive disease pre-lymphodepletion — a population with roughly 20-30% one-year progression-free survival.
Key figures
- Drug Name
- systemic recombinant human DNase (DNase I)
- Phase Of Trial
- investigator-initiated Phase 1b-style study
- Indication
- large B-cell lymphoma
- Dose regimen
- 1.0 mg/kg IV on Days 0, 3, 6, 10 and 15 post CAR T infusion
- Car t products
- ["tisagenlecleucel","axicabtagene ciloleucel","lisocabtagene maraleucel"]
- Enrollment target
- 12
- Primary endpoints
- ["ORR at 1 and 3 months","DOR","DCR","OS at 12 months"]
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.